Detalhe da pesquisa
1.
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.
Nephrol Dial Transplant
; 39(2): 328-340, 2024 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550217
2.
Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression.
Int J Mol Sci
; 25(11)2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38892211
3.
Effectiveness of mycophenolate mofetil in C3 glomerulonephritis.
Kidney Int
; 88(5): 1153-60, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26221755
4.
In response to the paper 'High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors?'
Diabetes Obes Metab
; 22(9): 1701-1702, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32424874
5.
Characterization of the plasma proteomic profile of Fabry disease: Potential sex- and clinical phenotype-specific biomarkers.
Transl Res
; 269: 47-63, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38395389
6.
The Spanish Fabry women study: a retrospective observational study describing the phenotype of females with GLA variants.
Orphanet J Rare Dis
; 18(1): 8, 2023 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36624527
7.
Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy.
Nefrologia (Engl Ed)
; 41(6): 652-660, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-36165155
8.
Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy.
Nefrologia (Engl Ed)
; 2021 Mar 10.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-33714629
9.
In response to the article "The challenge of cardiovascular disease in patients with chronic kidney disease".
Nefrologia (Engl Ed)
; 43(4): 511-512, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37813739
10.
Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab.
Nefrologia
; 34(3): 421-2, 2014 May 21.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-24849064